ImmunoCellular Therapeutics (IMUC) 8-K ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results

			Exhibit 99.2
Condensed Balance Sheets
		12/31/2013		12/31/2012
Cash and cash equivalents	$	27,646,351	$	26,216,668
Other current assets		763,299		714,508
Total current assets		28,409,650		26,931,176
Non current assets		531,027		88,025
	$	28,940,677	$	53,950,377
Current liabilities	$	1,402,273	$	1,098,307
Warrant liabilities		1,064,810		2,852,880
Shareholders' equity		26,473,594		23,068,014
	$	28,940,677	$	27,019,201
Condensed Statements of Operations
		Year		Year
		ended		ended
		12/31/2013		12/31/2012
Revenue	$	-	$	-
Research and development		5,339,716		7,711,233
Stock based compensation		724,212		496,007
General and administrative		3,396,391		3,619,291
Loss before other expenses		(9,460,319)		(11,826,531)
Interest income		17,345		8,609
Financing expense		-		(397,294)
Change in fair value of warrant liabilities		642,411		(2,279,923)
Net loss	$	(8,800,563)	$	(14,495,139)